Compare HOUS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOUS | PCRX |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2006 | 2011 |
| Metric | HOUS | PCRX |
|---|---|---|
| Price | $14.28 | $26.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $14.00 | ★ $32.86 |
| AVG Volume (30 Days) | ★ 1.5M | 858.0K |
| Earning Date | 02-12-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | ★ $5,874,000,000.00 | $716,791,000.00 |
| Revenue This Year | $6.82 | $6.24 |
| Revenue Next Year | $6.94 | $9.53 |
| P/E Ratio | ★ N/A | $55.31 |
| Revenue Growth | ★ 5.27 | 3.14 |
| 52 Week Low | $2.71 | $18.17 |
| 52 Week High | $15.14 | $27.64 |
| Indicator | HOUS | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 58.98 |
| Support Level | $13.94 | $25.56 |
| Resistance Level | $14.44 | $26.70 |
| Average True Range (ATR) | 0.53 | 0.94 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 33.08 | 59.77 |
Anywhere Real Estate Inc operates in residential real estate, focusing on brokerage, relocation, title, settlement businesses, and mortgage and title insurance ventures. It supports approximately 1 million home sale sides annually. Brands include Better Homes and Gardens, CENTURY 21, Coldwell Banker, Corcoran, ERA, and Sotheby's International Realty. Revenue comes mainly from existing home transactions. Operations are segmented into Anywhere Brands (franchises), Anywhere Advisors (owned brokerage), and Anywhere Integrated Services (title and settlement).
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.